MedTrace Logo

Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy

NCT01743014 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether the combination with ramipril and clopidogrel leads to further improvement of endothelial function, reduction of oxidative stress and reduction of vascular inflammation, compared with ramipril monotherapy, in patients with Diabetes Mellitus type 2 and diabetic nephropathy.

Conditions

  • Diabetes Type 2
  • Diabetic Nephropathy
  • Vascular Disease

Interventions

DRUG

Ramipril

Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks

DRUG

Clopidogrel

12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    collaborator OTHER

  • AHEPA University Hospital

    lead OTHER

Principal Investigators

  • Fotios S Iliadis, Lecturer of Internal Medicine · AHEPA University Hospital/ Aristotle University of Thessaloniki

  • Vaia F Bougatsa, Resident of Internal Medicine · AHEPA University Hospital/ Aristotle University of Thessaloniki

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-07-31
Completion
2015-07-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01743014 on ClinicalTrials.gov